{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:31:53Z","timestamp":1759624313761,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":5547,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.exphem.2007.01.022","type":"journal-article","created":{"date-parts":[[2007,3,30]],"date-time":"2007-03-30T09:42:59Z","timestamp":1175247779000},"page":"137-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"S","title":["Recent advances in myelodysplastic syndromes"],"prefix":"10.1016","volume":"35","author":[{"given":"Richard K.","family":"Shadduck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan M.","family":"Latsko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bushra","family":"Haq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifaa","family":"Abdulhaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2007.01.022_bib1","series-title":"Hematology: Basic Principles & Practice","first-page":"1106","article-title":"The myelodysplastic syndromes","author":"Greenberg","year":"2000"},{"key":"10.1016\/j.exphem.2007.01.022_bib2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMp048266","article-title":"Myelodysplastic syndromes-coping with ineffective hematopoiesis","volume":"352","author":"Cazzola","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2007.01.022_bib3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4065\/81.1.104","article-title":"The myelodysplastic syndromes: diagnosis and treatment","volume":"81","author":"Steensma","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"Suppl 5","key":"10.1016\/j.exphem.2007.01.022_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1634\/theoncologist.6-suppl_5-8","article-title":"Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes","volume":"6","author":"Silverman","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.exphem.2007.01.022_bib5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2007.01.022_bib6","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasm","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.01.022_bib7","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.01.022_bib8","first-page":"1272","article-title":"Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes","volume":"98","author":"Bellamy","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.01.022_bib9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/10428199009069295","article-title":"Apoptosis is a common histopathological finding in myelodysplasia, the correlate of ineffective hematopoiesis","volume":"2","author":"Clark","year":"1990","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2007.01.022_bib10","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0889-8588(03)00087-X","article-title":"Cytogenetics of chronic myeloproliferative disorders and related myelodysplastic syndromes","volume":"17","author":"Adeyinka","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.exphem.2007.01.022_bib11","series-title":"Clinical Hematology","first-page":"203","article-title":"Myelodysplastic syndrome","author":"Young","year":"2005"},{"key":"10.1016\/j.exphem.2007.01.022_bib12","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1182\/blood-2002-01-0096","article-title":"Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities","volume":"100","author":"Sloand","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.01.022_bib13","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.458.458","article-title":"Granulocyte colony stimulating factor preferentially causes proliferation of pre-existing monosomy 7 cells in aplastic anemia and myelodysplastic syndrome because of abnormal truncated GCSF-receptors on these cells","volume":"104","author":"Sloand","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.01.022_bib14","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1182\/blood.V86.12.4579.bloodjournal86124579","article-title":"Monosomy 7 and activating RAS mutations accompany malignant transformation in patients with congenital neutropenia","volume":"86","author":"Kalra","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.01.022_bib15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndrome: delayed transplantation for low risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.01.022_bib16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.1995.tb08909.x","article-title":"Efficacy of erythropoietin in the myelodysplastic syndromes: a meta analysis of 205 patients from 17 studies","volume":"89","author":"Hellstrom-Lindberg","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2007.01.022_bib17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/BF01811466","article-title":"Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment","volume":"64","author":"Verhoef","year":"1992","journal-title":"Ann Hematol"},{"key":"10.1016\/j.exphem.2007.01.022_bib18","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1056\/NEJM198712173172501","article-title":"Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes","volume":"317","author":"Vadhan-Raj","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2007.01.022_bib19","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1182\/blood.V87.10.4076.bloodjournal87104076","article-title":"Maintenance treatment of anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence of synergy","volume":"87","author":"Negrin","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.01.022_bib20","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood.V82.3.737.737","article-title":"Treatment of anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin","volume":"82","author":"Negrin","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.01.022_bib21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood.V92.1.68.413k23_68_75","article-title":"Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long term follow up of 71 patients","volume":"92","author":"Hellstorm-Lindberg","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.01.022_bib22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1046\/j.1365-2141.1997.4013211.x","article-title":"Erythroid response to treatment with G-CSF plus erythropoietin for the anemia patients with myelodysplastic syndromes: proposal for a predictive model","volume":"99","author":"Hellstrom-Lindberg","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2007.01.022_bib23","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1182\/blood.V97.5.1427","article-title":"Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes","volume":"97","author":"Bellamy","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.01.022_bib24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0925-5710(96)00455-0","article-title":"Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines","volume":"63","author":"Raza","year":"1996","journal-title":"Int J Hematol"},{"key":"10.1016\/j.exphem.2007.01.022_bib25","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood.V98.4.958","article-title":"Thalidomide produces transfusion independence in long standing refractory anemias of patients with myelodysplastic syndromes","volume":"98","author":"Raza","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2007.01.022_bib26","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes","volume":"352","author":"List","year":"2005","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2007.01.022_bib27","article-title":"Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: results of the Multicenter MDS-003 Study","volume":"23","author":"List","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.exphem.2007.01.022_bib28","article-title":"Results of the MDS-002 and \u2013003 International Phase II Studies evaluating lenalidomide (CC-5013; REVLIMID) in the treatment of transfusion\u2013dependent (TD) patients with myelodysplastic syndromes","volume":"90","author":"List","year":"2005","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2007.01.022_bib29","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1038\/ncponc0354","article-title":"DNA methylation and gene silencing in cancer","volume":"2","author":"Baylin","year":"2005","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.exphem.2007.01.022_bib30","first-page":"21","article-title":"Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes","volume":"7","author":"Silverman","year":"1993","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2007.01.022_bib31","article-title":"Azacitidine in myelodysplastic syndromes: CALGB studies 8421 and 8921","volume":"68","author":"Silverman","year":"1994","journal-title":"Ann Hematol"},{"key":"10.1016\/j.exphem.2007.01.022_bib32","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of Azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2007.01.022_bib33","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0145-2126(02)00028-0","article-title":"Treatment of myelodysplastic syndromes with 5-azacytidine","volume":"26","author":"Gryn","year":"2002","journal-title":"Leuk Res"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2007.01.022_bib34","first-page":"19","article-title":"Continuous infusion of low dose 5-Aza-2\u2032-deoxycytidine in elderly patients with high risk myelodysplastic syndrome","volume":"11","author":"Wijermans","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2007.01.022_bib35","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.2000.18.5.956","article-title":"Low dose 5-Aza-2\u2032-deoxycytidine, a DNA hypomethylating agent, for the treatment of high risk myelodysplastic syndrome: a multicenter phase II study in elderly patients","volume":"18","author":"Wijermans","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2007.01.022_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00277-005-0012-1","article-title":"An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2\u2032-deoxydytidine (decitabine) in 177 patients","volume":"84","author":"Wijermans","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.exphem.2007.01.022_bib37","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2007.01.022_bib38","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.2522.2522","article-title":"Decitabine low dose schedule (100 mg\/m2 \/Course) in myelodysplastic syndrome. Comparison of 3 different dose schedules","volume":"106","author":"Kantarjian","year":"2005","journal-title":"Blood"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X07000252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X07000252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:23:48Z","timestamp":1759566228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X07000252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0301472X07000252"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2007.01.022","relation":{},"ISSN":["0301-472X"],"issn-type":[{"type":"print","value":"0301-472X"}],"subject":[],"published":{"date-parts":[[2007,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in myelodysplastic syndromes","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2007.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}